Atossa Therapeutics Inc (NAS:ATOS)
$ 1.5 0 (0%) Market Cap: 188.64 Mil Enterprise Value: 109.11 Mil PE Ratio: 0 PB Ratio: 2.34 GF Score: 42/100

Q2 2023 Atossa Therapeutics Inc Earnings Call Transcript

Aug 14, 2023 / 01:00PM GMT
Release Date Price: $0.963 (-8.29%)
Operator

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to Atossa Therapeutics Q2 2023 conference call. Please be advised, today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Eric Van Zanten, Vice President of Investor and Public Relations. Mr. Van Zanten, you may begin.

Eric Van Zanten
Atossa Therapeutics, Inc. - VP, IR & Public Relations

Thank you, [Kevin]. Good morning, everyone and welcome to Atossa's second-quarter 2023 corporate and financial update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended June 30, 2023. The press release can be accessed on the investor portion of our website at investors.atossatherapeutics.com.

Joining me on the call today are Dr. Steven Quay, Atossa's President and Chief Executive Officer; and Greg Weaver, our Executive Vice President and Chief Financial Officer.

During today's call, we will be making

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot